Uniswap's decentralized exchange sees 62% of its tokenized-stock trading volume occur outside traditional U.S. market hours in a measured week. Tokenized stocks are digital versions of publicly traded shares, allowing trading beyond standard exchange times. This trend highlights growing interest in after-hours trading on decentralized platforms, potentially expanding market access for investors globally.
Uniswap's tokenized stocks trading volume outside U.S. market hours is noted here for context. For readers following major cryptocurrencies on Pluang as of Nov 12, 2026 05:22 WIB: out of 50 assets, 27 rose and 22 fell today. Filecoin (FIL) gained 2.97% to Rp13.938 with a typical hold time of 101 days and 100% buy order activity, contrasting with Stellar (XLM) at Rp2.699, up 2.90% with 95% buy orders and a shorter hold time of 85 days. Avalanche (AVAX) rose 2.89% to Rp155.245, with 81% buy orders and an 88-day hold time, showing varied investor engagement across these assets.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
